142344-87-4 Usage
General Description
GP 531 is a chemical compound that belongs to the class of glycopeptide antibiotics. It is synthesized from naturally occurring antibiotic vancomycin through chemical modifications, resulting in improved pharmacokinetic properties and enhanced antibacterial activity. GP 531 has been shown to exhibit potent in vitro activity against a wide range of Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). Additionally, GP 531 has demonstrated low toxicity and high stability, making it a promising candidate for the treatment of serious infections caused by multidrug-resistant pathogens. Further research and clinical trials are needed to fully evaluate the efficacy and safety of GP 531 as a potential therapeutic agent in the fight against antibiotic-resistant bacteria.
Check Digit Verification of cas no
The CAS Registry Mumber 142344-87-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,2,3,4 and 4 respectively; the second part has 2 digits, 8 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 142344-87:
(8*1)+(7*4)+(6*2)+(5*3)+(4*4)+(3*4)+(2*8)+(1*7)=114
114 % 10 = 4
So 142344-87-4 is a valid CAS Registry Number.
InChI:InChI=1/C16H21N5O4/c17-14-11(15(18)24)20-8-21(14)16-13(23)12(22)10(25-16)7-19-6-9-4-2-1-3-5-9/h1-5,8,10,12-13,16,19,22-23H,6-7,17H2,(H2,18,24)/t10-,12-,13-,16-/m1/s1
142344-87-4Relevant articles and documents
METHODS, COMPOSITIONS, AND FORMULATIONS FOR PREVENTING OR REDUCING ADVERSE EFFECTS IN A PATIENT
-
Page/Page column 35, (2008/12/07)
The present invention provides transdermal administration of AICA riboside, or a prodrugs, analogs, or salts thereof, and/or a blood clotting inhibitor for preventing or reducing adverse side effects in a patient. The type of patient that may benefit incl
